Home > News > Biophan Names John Lanzafame President of New Nanolution Division
September 16th, 2004
Biophan Names John Lanzafame President of New Nanolution Division
Biophan Technologies, Inc., a developer of next-generation biomedical technology, has appointed biotechnology executive John Lanzafame to serve as president of the Company's Nanolution division, according to Biophan CEO Michael Weiner.
As Nanolution president, Mr. Lanzafame will oversee Biophan's development of advanced nanotechnology-based drug delivery devices and drug-elution technologies, patents, and products.
Evidence mounts for quantum criticality theory: Findings bolster theory that quantum fluctuations drive strange electronic phenomena January 30th, 2015
Everything You Need To Know About Nanopesticides January 30th, 2015
DNA nanoswitches reveal how life's molecules connect: An accessible new way to study molecular interactions could lower cost and time associated with discovering new drugs January 30th, 2015
Crystal light: New light-converting materials point to cheaper, more efficient solar power: University of Toronto engineers study first single crystal perovskites for new solar cell and LED applications January 30th, 2015
Nexeon Board Changes Announced January 29th, 2015
Rice's Naomi Halas to direct Smalley Institute: Optics pioneer will lead Rice's multidisciplinary science institute January 15th, 2015
SUNY Board Appoints Dr. Alain Kaloyeros as Founding President of SUNY Polytechnic Institute January 13th, 2015
Blend Therapeutics Appoints Distinguished Physician Scientist, Dennis Ausiello, MD, to Board of Directors January 8th, 2015